+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Chronic Treatment with Thyrotropin-Releasing Hormone (TRH) or an Analog of TRH (Linear β-Alanine TRH) on the Hypothalamic-Pituitary-Thyroid Axis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The effects of treatment for 5 or 9 days with varying doses of thyrotropin-releasing hormone (TRH) or the linear β-alanine TRH congener (pGlu-His-Pro- β-Ala-NH<sub>2</sub>) on serum levels of TSH, T<sub>3</sub> and T<sub>4</sub> were studied in mice and rats. At low doses in rats treatment with TRH for 9 days significantly increased serum levels of T<sub>3</sub> but not serum T<sub>4</sub> whereas a higher dose of TRH (10 mg/kg) reduced serum T<sub>3</sub> levels. β-ALA TRH (0.1–10 mg/kg IP) treatment for 9 days in rats significantly reduced serum T<sub>4</sub> levels whereas serum T<sub>3</sub> levels were only depressed at higher doses (1–10 mg/kg IP) of the peptide. In mice treatment for 5 days with TRH (1 and 10 mg/kg IP) significantly reduced serum levels of T<sub>3</sub> and T<sub>4</sub>. In addition, TRH (0.1–10 mg/kg IP) or β-ALA·TRH treatment (1.0–10 mg/kg IP) for 9 days significantly reduced serum TSH levels in rats. TRH (10 mg/kg IP for 9 days) also significantly reduced serum GH levels in rats. No alteration in hypothalamic content of TRH or LHRH was observed after chronic TRH treatment. Some, but not all, of our findings support the hypothesis that treatment with high doses of TRH reduce pituitary-thyroid axis functions by a direct effect on hypophysial TRH receptors.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 30
          : 4
          : 193-199
          Biological .RSciences Research Center, Neurobiology Program, Departments of Psychiatry, Pharmacology and Medicine, University of North Carolina School of Medicine, Chapel Hill, N.C.; Division of Neurology, Montreal General Hospital, McGill University, Montreal, Queb., and Peptide Biology Laboratory, Salk Institute for Biological Studies, La Jolla, Calif.
          123000 Neuroendocrinology 1980;30:193–199
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article